专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明申请

WO1993006135A1 DIAGNOSING AND TREATING AUTOIMMUNE DISORDERS 审中-公开
标题翻译：诊断和治疗自身免疫性疾病
公开(公告)号：WO1993006135A1
公开(公告)日：1993-04-01
申请号：PCT/US1992008094
申请日：1992-09-23
申请人： GENENTECH, INC. , AMENTO, Edward, P.
发明人： GENENTECH, INC.
IPC分类号： C07K15/06
CPC分类号： C07K14/7051 , A61K38/00 , C07K16/2809
摘要： Rheumatoid arthritis patients preferentially use the T-cell receptor domains V beta 14, V beta 7, V beta 8, V beta 12, V beta 13, V beta 15, V beta 2.2, V beta 2.3, J beta 2.1, J beta 2.5, J beta 2.7, and C beta 2. Patients are treated with polypeptides containing sequences from these domains or with antibodies capable of specifically binding these domains. Improved methods for diagnosing V beta usage in autoimmune disease are provided. The use of J beta polypeptides and antibodies for the treatment of autoimmune disorders is new.
摘要翻译：类风湿性关节炎患者优先使用T细胞受体结构域Vβ14，Vβ7，Vβ8，Vβ12，Vβ13，Vβ15，Vβ2.2，Vβ2.3，Jβ2.1，Jβ2.5 ，J beta 2.7和C beta 2.患者用含有来自这些结构域的序列的多肽或能够特异性结合这些结构域的抗体处理。提供了用于诊断自身免疫性疾病中Vβ使用的改进方法。使用Jβ多肽和抗体治疗自身免疫性疾病是新的。

82. 发明申请

WO1993004173A1 IMMUNOGLOBULIN VARIANTS FOR SPECIFIC FC EPSILON RECEPTORS 审中-公开
标题翻译：特异性FC EPSILON受体的免疫球蛋白变体
公开(公告)号：WO1993004173A1
公开(公告)日：1993-03-04
申请号：PCT/US1992006860
申请日：1992-08-14
申请人： GENENTECH, INC. , JARDIEU, Paula, M. , PRESTA, Leonard, G.
发明人： GENENTECH, INC.
IPC分类号： C12N15/12
CPC分类号： C07K16/32 , A61K38/00 , A61K2039/505 , C07K16/00 , C07K16/18 , C07K16/4291 , C07K16/468 , C07K2317/24 , C07K2317/52 , C07K2317/526 , C07K2317/565
摘要： Two classes of polypeptides derived from human IgE are described. One class binds selectively to the high affinity IgE receptor on mast cells and basophils, but not to the low affinity IgE receptor on B-cells, monocytes, eosinophils and platelets. The other class binds to the low affinity receptor, but not the high affinity receptor. The differential binding polypeptides of this invention are useful in diagnostic procedures for IgE receptors or in the therapy of IgE-mediated disorders such as allergies. They also are useful in preparing antibodies capable of binding regions of IgE that participate in receptor binding.
摘要翻译：描述了衍生自人IgE的两类多肽。一类与肥大细胞和嗜碱性粒细胞上的高亲和力IgE受体有选择性结合，但不结合B细胞，单核细胞，嗜酸性粒细胞和血小板上的低亲和力IgE受体。另一类与低亲和力受体结合，但不结合高亲和力受体。本发明的差异结合多肽可用于IgE受体的诊断程序或IgE介导的疾病如过敏的治疗。它们也可用于制备能够结合参与受体结合的IgE区域的抗体。

83. 发明申请

WO1992019281A2 NEW CONJUGATES, CONSISTING OF A GLYCOPROTEIN AND A NUCLEIC ACID-BINDING SUBSTANCE 审中-公开
标题翻译：新型糖尿病与核酸结合物质的联合
公开(公告)号：WO1992019281A2
公开(公告)日：1992-11-12
申请号：PCT/EP1992000953
申请日：1992-05-01
申请人： GENENTECH, INC. , BOEHRINGER INGELHEIM INTERNATIONAL GMBH , BIRNSTIEL, Max, L. , COTTEN, Matthew , WAGNER, Ernst
发明人： GENENTECH, INC. , BOEHRINGER INGELHEIM INTERNATIONAL GMBH
IPC分类号： A61K47/48
CPC分类号： A61K47/6883 , A61K47/645
摘要： New conjugates in which a glycoprotein and a nucleic acid binding substance are connected by the carbohydrate moiety of the glycoprotein can be used to import therapeutically or gene-therapeutically efficacious nucleic acids into cells which express on their surface a protein to which the glycoprotein binds. The preferred glycoprotein is transferrin, the preferred nucleic acid-binding substance is a homologous polycationic polypeptide such as polylysine. The conjugates can be prepared by oxidizing the carbohydrate group of the glycoprotein, in particular, sialic acid, to the aldehyde form and coupling it with the nucleic acid binding substance, which preferably contains amino groups. Complexes containing the conjugates and an efficacious nucleic acid are ingredients of pharmaceutical preparations for therapeutic or gene-therapeutic application.

84. 发明申请

WO1992017497A1 HUMAN PF4A RECEPTORS AND THEIR USE 审中-公开
标题翻译：人类PF4A受体及其使用
公开(公告)号：WO1992017497A1
公开(公告)日：1992-10-15
申请号：PCT/US1992002317
申请日：1992-03-23
申请人： GENENTECH, INC.
发明人： GENENTECH, INC. , LEE, James , HOLMES, William, E. , WOOD, William, I.
IPC分类号： C07K15/00
CPC分类号： C07K16/2866 , A61K38/00 , A61K39/00 , C07K14/7155 , C07K2319/00
摘要： cDNAs encoding a class of novel PF4ARs has been identified in human tissue. Provided herein are nucleic acid sequences of three PF4ARs (including the human IL-8 receptor) useful as a diagnostic and in the recombinant preparation of PF4ARs. The PF4ARs are used in the preparation and purification of antibodies capable of binding to the receptors, and in diagnostic assays.
摘要翻译：已经在人体组织中鉴定出编码一类新型PF4AR的cDNA。本文提供了可用作诊断和PF4AR重组制备的三种PF4AR（包括人IL-8受体）的核酸序列。 PF4AR用于制备和纯化能够结合受体的抗体，并用于诊断测定。

85. 发明申请

WO1992011377A1 TISSUE PLASMINOGEN ACTIVATOR SUBSTITUTION VARIANT 审中-公开
标题翻译：组织培养基激活剂替代品
公开(公告)号：WO1992011377A1
公开(公告)日：1992-07-09
申请号：PCT/US1991009455
申请日：1991-12-16
申请人： GENENTECH, INC.
发明人： GENENTECH, INC. , BENNETT, William, F., III
IPC分类号： C12N15/58
CPC分类号： C12N9/6459 , A61K38/00 , C12Y304/21069
摘要： Biologically active tissue plasminogen activator (t-PA) variants with greatly increased clot lysis activity as compared to wild-type t-PA are prepared, wherein the arginine residue at position 299 is replaced by an aspartic acid residue. DNA sequences can be prepared that encode the variants, as well as expression vectors incorporating the DNA sequences and host cells transformed with the expression vectors. The variants may be used in pharmaceutical preparations to treat a vascular disease or condition, or to prevent fibrin deposition or adhesion formation or reformation in mammals.
摘要翻译：制备与野生型t-PA相比具有大大提高的凝块溶解活性的生物活性组织纤溶酶原激活物（t-PA）变体，其中299位的精氨酸残基被天冬氨酸残基替代。可以制备编码变体的DNA序列，以及掺入DNA序列的表达载体和用表达载体转化的宿主细胞。这些变体可用于药物制剂中以治疗血管疾病或病症，或用于预防哺乳动物中纤维蛋白沉积或粘附形成或重组。

86. 发明申请

WO1992009690A2 ENRICHMENT METHOD FOR VARIANT PROTEINS WITH ALTERED BINDING PROPERTIES 审中-公开
标题翻译：具有改变的结合性质的变体蛋白的富集方法
公开(公告)号：WO1992009690A2
公开(公告)日：1992-06-11
申请号：PCT/US1991009133
申请日：1991-12-03
申请人： GENENTECH, INC. , GARRARD, Lisa, J. , HENNER, Dennis, J. , BASS, Steven , GREENE, Roland , LOWMAN, Henry, B. , WELLS, James, A. , MATTHEWS, David, J.
发明人： GENENTECH, INC.
IPC分类号： C12N15/00
CPC分类号： C40B40/02 , C07K14/005 , C07K14/575 , C07K14/61 , C07K2319/00 , C07K2319/02 , C07K2319/735 , C07K2319/75 , C12N15/1037 , C12N15/62 , C12N2750/00011 , C12N2795/14022 , C12N2795/14122 , G01N33/6845 , G01N33/74 , G01N2333/61 , Y10S436/802 , Y10S930/12
摘要： A method for selecting novel proteins such as growth hormone and antibody fragment variants having altered binding properties for their respective receptor molecules is provided. The method comprises fusing a gene encoding a protein of interest to the carboxy terminal domain of the gene III coat protein of the filamentous phage M13. The gene fusion is mutated to form a library of structurally related fusion proteins that are expressed in low quantity on the surface of a phagemid particle. Biological selection and screening are employed to identify novel ligands useful as drug candidates. Disclosed are preferred phagemid expression vectors and selected human growth hormone variants.
摘要翻译：提供了选择新型蛋白质如生长激素和具有改变其各自受体分子的结合特性的抗体片段变体的方法。该方法包括将编码目标蛋白的基因融合到丝状噬菌体M13的基因III外壳蛋白的羧基末端结构域上。基因融合突变以形成在噬菌粒粒子表面上以低量表达的结构相关融合蛋白的文库。使用生物选择和筛选来鉴定可用作候选药物的新型配体。公开了优选的噬菌粒表达载体和选择的人生长激素变体。

87. 发明申请

WO1992008985A2 LIGAND-MEDIATED IMMUNOFUNCTIONAL HORMONE BINDING PROTEIN ASSAY METHOD 审中-公开
标题翻译：配体介导的免疫功能性激素结合蛋白测定
公开(公告)号：WO1992008985A2
公开(公告)日：1992-05-29
申请号：PCT/US1991008664
申请日：1991-11-19
申请人： GENENTECH, INC. , CARLSSON, Lena, Mariana, Susann , CLARK, Ross, Graham , WONG, Wai, Lee, Tan
发明人： GENENTECH, INC.
IPC分类号： G01N33/74
CPC分类号： C07K16/26 , A61K38/00 , C07K14/72 , C07K16/2869 , G01N33/74 , G01N2333/61 , G01N2333/65 , Y10S435/975
摘要： A ligand-mediated immunofunctional assay (LIFA) method for detecting the presence and the concentration of polypeptide hormone binding proteins which comprises capturing the binding protein with a solid phase bound first antibody, saturating the bound hormone binding protein with the ligand polypeptide hormone, and detecting the bound ligand polypeptide hormone with a detectably labeled second antibody specific for the ligand polypeptide hormone. In the absence of added saturating polypeptide hormone, the LIFA measures the amount of hormone binding protein bound to the endogenous ligand polypeptide hormone. A growth hormone binding protein assay illustrates the method of the present invention. LIFA assay results indicate that increased binding protein substantially increases growth hormone activity. Methods of use and formulations of growth hormone binding protein, growth hormone, insulin-like growth factor-I and insulin-like growth factor binding protein are disclosed.
摘要翻译：用于检测多肽激素结合蛋白的存在和浓度的配体诱导免疫功能测定（LIFA）方法包括用固相结合的第一抗体捕获结合蛋白使其饱和激素结合蛋白与多肽激素配体结合，并使用对配体的多肽激素特异的第二种可检测标记的抗体检测配体结合的多肽激素。在没有添加饱和多肽激素的情况下，LIFA测量与内源性配体的多肽激素结合的激素结合蛋白的量。生长激素结合蛋白的分析说明了本发明的方法。 LIFA测定的结果表明增加的结合蛋白显着增加生长激素的活性。还公开了使用方法以及生长激素结合，生长激素，胰岛素样生长因子-I和生长因子结合蛋白制剂。胰岛素样。

88. 发明申请

WO1992007090A1 METHODS FOR MODIFYING AND DETECTING THE EFFECTS ON THE INTERACTION OF MODIFIED POLYPEPTIDES AND TARGET SUBSTRATES 审中-公开
标题翻译：修饰和检测改性多聚物和目标基质相互作用效果的方法
公开(公告)号：WO1992007090A1
公开(公告)日：1992-04-30
申请号：PCT/US1991007506
申请日：1991-10-21
申请人： GENENTECH, INC.
发明人： GENENTECH, INC. , BOTSTEIN, David , PALZKILL, Timothy
IPC分类号： C12Q01/68
CPC分类号： C12N15/102
摘要： The invention relates to methods and mutation linkers to modify DNA, to methods for producing libraries containing a multiplicity of modified DNA, and to methods for using such libraries for screening modified proteins encoded by such DNA. The DNA targeted for modification typically encodes a polypeptide such as an enzyme. The libraries are used to determine the effect of such modification or the interaction of the modified polypeptides with a target. In preferred embodiments, the invention relates to methods for making and using libraries containing DNA encoding modified antibiotic hydrolases to screen antibiotics against one or more of the modified antibiotic hydrolases produced by such libraries. Susceptibility or lack of susceptibility of an antibiotic to neutralizaation provides an indication of whether wild-type antibiotic hydrolases are likely to mutate to confer resistance to the antibiotic.
摘要翻译：本发明涉及用于修饰DNA的方法和突变接头，用于产生含有多个修饰的DNA的文库的方法，以及使用这种文库筛选由此DNA编码的修饰蛋白的方法。靶向修饰的DNA通常编码多肽，例如酶。文库用于确定这种修饰的作用或修饰的多肽与靶标的相互作用。在优选的实施方案中，本发明涉及制备和使用含有编码经修饰的抗生素水解酶的DNA的文库以筛选针对一种或多种由这些文库产生的修饰的抗生素水解酶的抗生素的方法。敏感性或抗生素对中和敏感性的敏感性提供了野生型抗生素水解酶是否可能突变以赋予抗生素抗性的指征。

89. 发明申请

WO1991018621A1 THE COMBINATION OF GROWTH HORMONE AND INSULIN-LIKE GROWTH FACTOR-I ENHANCES GROWTH 审中-公开
标题翻译：生长激素与胰岛素样生长因子的组合增加增加
公开(公告)号：WO1991018621A1
公开(公告)日：1991-12-12
申请号：PCT/US1991003841
申请日：1991-05-31
申请人： GENENTECH, INC.
发明人： GENENTECH, INC. , CLARK, Ross, G. , CRONIN, Michael, J.
IPC分类号： A61K37/24
CPC分类号： A61K9/0019 , A61K38/27 , A61K38/30 , A61K47/10 , A61K47/12 , A61K47/26 , A61K2300/00
摘要： A method is disclosed for enhancing growth of a mammal by administration of a combination of effective amounts of IGF-I and GH so as to enhance the growth of the mammal over the enhancement in growth achieved using either IGF-I or GH alone in an amount equal to that used for either IGF-I or GH, respectively, in the combination. Preferably, the mammal is a child, the IGF-I is native-sequence, mature human IGF-I or human brain IGF-I, and the GH is native-sequence, mature human GH with or without a terminal methionine. In another preferred embodiment, the mammal is a non-human animal of economic importance such as a cow or pig.

90. 发明申请

WO1991018047A1 MAMMALIAN EXPRESSION OF THE BMP-2 FAMILY 审中-公开
标题翻译：哺乳动物BMP-2家族的表达
公开(公告)号：WO1991018047A1
公开(公告)日：1991-11-28
申请号：PCT/US1991003540
申请日：1991-05-20
申请人： GENENTECH, INC.
发明人： GENENTECH, INC. , HAMMONDS, R., Glenn , MASON, Anthony, J.
IPC分类号： C08J07/18

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式